Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
FUJIFILM Healthcare Americas Corp.
| Company | FUJIFILM Healthcare Americas Corp. |
|---|---|
| Name of instrument | µTASWako i30 |
| Contact | Amador Alejo |
| City, State | Lexington, MA |
| Phone | 877-714-1924 |
| Website | |
| Type of instrument | immunoassay |
| List price/First year sold in U.S. | —/2011 |
| Targeted hospital bed size/Targeted test volume | — |
| Company manufactures instrument | no (manufactured by FUJIFILM Wako Pure Chemical Corp.) |
| Other models in this family of analyzers | — |
| No. of units in clinical use in U.S./Outside U.S. (countries) | 25/400 (Canada, Germany, Japan, China, South Korea, Vietnam, Thailand, Malaysia, Philippines) |
| Dimensions (H × W × D)/Instrument footprint | 21.5 × 20.5 × 23.4 in./3.34 sq. ft. |
| Weight empty/Weight fully loaded | 157 lbs./— |
| No. of different measured assays onboard simultaneously | 6 (6 can be run and calibrated at one time) |
| No. of user-definable (open chemistry) channels | 0 |
| Test throughput per hour/Assay run time | 25/— |
| No. of direct ion-selective electrode channels | — |
| Detection methods | — |
| Stat time until completion/specimen throughput for Ion-selective electrode | — |
| Stat time until completion/specimen throughput for Ion-selective electrode basic metabolic panel | — |
| Stat time until completion/specimen throughput for Ion-selective electrode complete metabolic panel | — |
| Typical time delay from ordering stat test until aspiration of sample | — |
| Fully automated microplate immunoassay system | no |
| Methodologies supported | fluorescence |
| Separation methodologies | microcapillary gel electrophoresis |
| Stat time until completion of a ß-hCG test | — |
| Stat time until completion of a cTn test | — |
| • Typical time delay from test order to aspiration of sample | — |
| Reagents refrigerated onboard/Reagents ready to use | yes (2°–10°C)/yes |
| Reagent lot tracking/Reagent inventory | yes/yes |
| Reagent form/Reagents barcoded | liquid chemistry (closed reagent system)/no |
| Separate reagent pack for each specimen/for each test run | no/no |
| Walkaway capability/Walkaway duration | yes/190 min. or 50 specimens or 80 tests |
| Design of sample-handling system | rack |
| Uses washable cuvettes/Uses disposable cuvettes | no/no |
| Min.–max. sample volume that can be aspirated at one time | 3 µL minimum |
| Min. reaction volume/Min. specimen volume/Min. dead volume | —/75 µL/72 µL |
| Dedicated pediatric sample cup | no |
| Primary tube sampling | yes |
| Accommodates most standard tube sizes/Accepts nonstandard tube sizes | yes/yes |
| Pierces caps on primary tubes | no |
| Protects against probe collision | yes |
| Detects clots/liquid level/short sample | yes/yes/yes |
| Detection or quantitation for hemolysis, icterus, lipemia, clots | hemolysis, icterus, lipemia, clots not available |
| Dilutes patient samples onboard/Susceptibility to carryover | no/0.1 parts per million |
| Automatic rerun capability | yes |
| Sample volume can be diluted to rerun out-of-linear-range high results | yes |
| Sample volume can be concentrated to rerun out-of-linear-range low results | no |
| Autocalibration/Multipoint calibration supported | yes (calibrants are not stored onboard)/— |
| Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays | — |
| Automatic programmable start/Automatic programmable shutdown | no/no |
| Onboard real-time QC/Onboard software capability to review QC | no/yes |
| Supports multiple QC lot numbers per analyte | yes |
| Waste management | automated collection onboard instrument |
| Sample barcode-reading capability/Autodiscrimination | yes (Interleaved 2 of 5, UPC, Codabar, Code 39, Code 128, ITF, EAN/JAN-13, EAN/JAN-18, STF(5BER), EAN-128)/yes |
| Lab can control analyzer from remote computer | no |
| Instrument can diagnose its own malfunctions | no (operator intervention required to order parts) |
| System malfunctions can be diagnosed via remote monitoring | no |
| UPS backup power supply | no |
| Data-management capability/LIS or EHR systems interfaced | onboard/— |
| LIS interface provided/Bidirectional interface capability | no/yes (host query) |
| Modem servicing provided/Service engineer on-site response time | no/based on contract |
| Mean time between failures | — (displays error codes for troubleshooting) |
| Average scheduled maintenance time by lab personnel | daily: 0; weekly: 0; monthly: 15 min. |
| Maintenance records kept onboard for user/vendor | no/— |
| Maintenance training demonstration module onboard | no |
| Training included with purchase/Avg. time for basic user training | yes/~2 days (at customer site) |
| Advanced operator training/Extra charge for follow-up or advanced training | — |
| Warranty provided/Cost of annual service contract (24 h/7 d) | yes (1 year)/— |
| Distinguishing features (supplied by company) | microfluidics technology; small footprint–tabletop; liver cancer risk biomarkers (AFP-L3, DCP) for hepatocellular carcinoma surveillance (in vitro diagnostic use); small sample volume; fast turnaround time |